EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety of intravenous and subcutaneous belimumab in Japanese patients with systemic lupus erythematosus: Final analysis of data from an all-case post-marketing surveillance study

Nami Okamoto iD, Takao Fujii, Tatsuya Atsumi iD, Asami Abe, Nobunori Takahashi, Naoto Tamura iD, Atsuo Nakajima, Ayako Nakajima, Shingo Nakayamada iD, Keiichiro Nishida, Hiroaki Matsuno, Tomohiko Asamura und 11 weitere

Modern Rheumatology · 04.11.2026 · 36 (6) · 950-963

DOI: 10.1093/mr/roag066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, online erschienen am 19.08.2026. Verfasst von Nami Okamoto und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Osaka Rosai Hospital, Osaka, Japan. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antibodies, Monoclonal, Humanized, Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess safety of belimumab in Japanese patients with systemic lupus erythematosus in real-world clinical practice.

Methods

This all-case post-marketing surveillance study included patients initiating belimumab between December 2017 and October 2018. To evaluate safety, patients were observed for up to 52 weeks. In main population, baseline risk factors for serious infection were assessed by multivariate analysis. Exploratory risk factor analysis for depression/suicidal ideation/suicide attempt was conducted in expanded population.

Results

Among 1177 patients (main population), incidence rates per 100 person-years of serious adverse events and adverse events of special interest were: serious adverse events, 28.4; serious infection, 8.8; depression/suicidal ideation/suicide attempt, 1.3; malignant tumour, 0.7; serious hypersensitivity, 0.7. Male sex, any comorbidity, and glucocorticoid dose at baseline were independent risk factors for serious infection. In an exploratory analysis, comorbidity of depression/suicidal ideation/suicide attempt at belimumab initiation was an associated characteristic factor for the new occurrence/worsening depression/suicidal ideation/suicide attempt.

Conclusions

No new safety concerns were identified compared with previously reported data and current belimumab labelling. The incidence rate of depression/suicidal ideation/suicide attempt was similar to that previously reported for patients with systemic lupus erythematosus. Patients with risk factors for serious infection and depression/suicidal ideation/suicide attempt should be carefully monitored.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicAntibodies, Monoclonal, HumanizedImmunosuppressive AgentsHumansFemaleMaleProduct Surveillance, PostmarketingAdultMiddle AgedJapanInjections, SubcutaneousRisk FactorsAgedEast Asian People

Stichwörter der Autor:innen

BelimumabJapanpost-marketing surveillance studysafetysystemic lupus erythematosus

Substanzen

belimumabAntibodies, Monoclonal, HumanizedImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Pediatrics, Osaka Rosai Hospital, Osaka, Japan.
  • Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan.
  • Department of Rheumatology, Endocrinology, and Nephrology, Hokkaido University, Sapporo, Hokkaido, Japan.
  • Department of Rheumatology, Niigata Rheumatic Center, Niigata, Japan.
  • Department of Orthopedic Surgery, Aichi Medical University, Nagakute, Aichi, Japan.
  • Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan.

ORCID-Profile: Nami Okamoto, Tatsuya Atsumi, Naoto Tamura, Shingo Nakayamada, Michiaki Takagi, Sakae Tanaka, Yoshiya Tanaka, Masataka Kuwana

Förderung

  • GSK

Zitieren

APA

Okamoto, N., Fujii, T., Atsumi, T., Abe, A., Takahashi, N., Tamura, N., Nakajima, A., Nakajima, A., Nakayamada, S., Nishida, K., Matsuno, H., Asamura, T., Koyano, M., Hayashi, A., Yoshida, M., Noda, D., Kaneko, N., Saito, S., Takagi, M., …, & Kuwana, M. (2026). Safety of intravenous and subcutaneous belimumab in Japanese patients with systemic lupus erythematosus: Final analysis of data from an all-case post-marketing surveillance study. Modern Rheumatology, 36(6), 950-963. https://doi.org/10.1093/mr/roag066

Vancouver

Okamoto N, Fujii T, Atsumi T, Abe A, Takahashi N, Tamura N, et al. Safety of intravenous and subcutaneous belimumab in Japanese patients with systemic lupus erythematosus: Final analysis of data from an all-case post-marketing surveillance study. Modern Rheumatology. 2026;36(6):950-963. doi:10.1093/mr/roag066

BibTeX
@article{Okamoto2026,
  author = {Okamoto, Nami and Fujii, Takao and Atsumi, Tatsuya and Abe, Asami and Takahashi, Nobunori and Tamura, Naoto and Nakajima, Atsuo and Nakajima, Ayako and Nakayamada, Shingo and Nishida, Keiichiro and Matsuno, Hiroaki and Asamura, Tomohiko and Koyano, Megumi and Hayashi, Ai and Yoshida, Mitsuhiro and Noda, Daisuke and Kaneko, Naoki and Saito, Shuntaro and Takagi, Michiaki and Tanaka, Sakae and Takeuchi, Tsutomu and Tanaka, Yoshiya and Kuwana, Masataka},
  title = {Safety of intravenous and subcutaneous belimumab in Japanese patients with systemic lupus erythematosus: Final analysis of data from an all-case post-marketing surveillance study},
  journal = {Modern Rheumatology},
  year = {2026},
  volume = {36},
  number = {6},
  pages = {950--963},
  doi = {10.1093/mr/roag066}
}
Kostenlos starten →